Abstracts

DARPins as Entry Inhibitor Alternative to HIV-1 Broadly Neutralizing Antibodies

Background: Development of drugs that share the properties of broadly neutralizing antibodies (BNAbs) is highly desirable. Here we utilize the Designed Ankyrin Repeat Protein (DARPin) technology to generate HIV-1 inhibitors with broad neutralization activity directed against the V3 loop. DARPins, small synthetic binding proteins with high target affinities and specificities, have interesting properties as anti-HIV…

Use of Pre-ART-Adjusted Endpoints in the Analysis of an HIV Therapeutic Vaccine Trial

Background: In one of the largest randomized, double-blind, placebo-controlled phase 2 therapeutic HIV vaccine clinical trials, Vacc-4x was found safe, well-tolerated and immunogenic. While on combination antiretroviral therapy (cART), 135 HIV-infected participants (vaccine: placebo = 92: 43) were randomized and received 4 weekly immunizations followed by booster immunizations at weeks 16 and 18. At week…

Decreased HIV-Specific T-Regulatory Responses Mark Effective Vaccine-Induced Immunity

Background: The role of regulatory T cells (Tregs) in vaccination has been poorly investigated. We have reported that vaccination with ex vivo-generated dendritic-cells (DC) loaded with HIV-lipopeptides (LIPO-5-DC vaccine) in HIV-infected patients was well tolerated and highly immunogenic. However, patients responded differently to vaccination. Here we hypothesized that the presence and/or induction of HIV-specific Tregs…

Viral Reservoir Dynamics After Therapeutic Vaccination and cART Interruption

Background: We reported a decrease viral set-point of 1.2 log10 associated with an increase in HIV-1–specific T cell responses in HIV infected individuals receiving autologous myeloid derived dendritic cells (MDDC) pulsed with autologous heat-inactivated whole HIV. Here, we assessed changes in viral reservoirs during vaccinations and the dynamics of viral reservoir replenishment during cART interruption…

HIV-1 Envelope Epitope Recognition Is Influenced by Immunoglobulin DH Gene Segment Repertoire

Background: HIV-1-specific broadly neutralizing antibodies (BnAbs), such as the membrane proximal external region (MPER) antibodies 2F5 and 4E10, contain long H chain complementarity determining region 3 (CDR-H3) which is encoded by DH gene segment, that lacks tyrosine and includes patches of hydrophobic and charged amino acids. However, B cells bearing Igs with charged or hydrophobic…

Human Rhinovirus Displaying HIV-1 4E10 Epitope Elicits Broad Neutralization in hICAM-1 Tg Mice

Background: Induction of bnAbs remains a critical goal towards developing a vaccine against HIV-1. We previously grafted 4E10 epitope of HIV-1 gp41 on the surface of human rhinovirus connected via linkers of varying lengths and sequences to construct combinatorial HRV display libraries. One chimeric HRV:HIV immunoselected from the libraries was able to elicit broad neutralization…

A Superagonist Antibody to Human Interleukin-21 Increases HIV-Specific T-Cell Function

Background: Interleukin-21 (IL-21) is an immunostimulatory cytokine showing promising results in phase II clinical trials for cancer immunotherapy. IL-21 also enhances anti-viral immunity in HIV/SIV infections. It is a suitable candidate that can be targeted by the kick and kill strategy to boost immunity to eliminate HIV. This study focused on developing an agonistic monoclonal…

Nonclassical Regulatory HIV-1–Specific CD8 T Cells in HIV-1 Disease Progression

Background: Regulatory T cells may influence HIV-1 disease progression by suppressing immune activation or inhibiting antiviral T cell immune responses. Recently, a distinct population of non-classical regulatory T cells expressing HLA-G was identified. However, the role of HLA-G-expressing T cells specific for HIV-1 is unknown. Methods: 36 HIV-1-specific and 25 CMV/EBV-specific CD8 T cell responses…